Suscriptores   Asóciese  
Textos Completos Autorizados
EL DIAGNOSTICO PRECOZ ES FUNDAMENTAL EN LA ENFERMEDAD DE PARKINSON

v-estudie-lo-mejor.gif
Expertos Invitados





EL DIAGNOSTICO PRECOZ ES FUNDAMENTAL EN LA ENFERMEDAD DE PARKINSON

(especial para SIIC © Derechos reservados)
La capacidad de detectar en etapas tempranas el proceso de la neurodegeneración abre una promisoria opción para instaurar tratamientos neuroprotectores que alteren el curso progresivo que caracteriza la enfermedad de Parkinson.
Autor:
Carlos Andrés Juri Clavería
Columnista Experto de SIIC

Institución:
Pontificia Universidad Católica de Chile

Artículos publicados por Carlos Andrés Juri Clavería
Coautor
Reinaldo Uribe San Martín* 
Alumno-Interno de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile*
Recepción del artículo
23 de Abril, 2008 		Aprobación
14 de Julio, 2008
Primera edición
11 de Diciembre, 2008 		Segunda edición, ampliada y corregida
7 de Junio, 2021

EL DIAGNOSTICO PRECOZ ES FUNDAMENTAL EN LA ENFERMEDAD DE PARKINSON

Resumen
La enfermedad de Parkinson (EP) se caracteriza por la presencia de síntomas motores que aparecen cuando ha ocurrido una extensa pérdida de neuronas dopaminérgicas a nivel de la sustancia negra. En las últimas décadas diversos hallazgos mostraron que el inicio del proceso degenerativo tiene lugar varios años antes de la aparición de los síntomas, involucrando numerosos sistemas de neurotransmisión. Diversas manifestaciones clínicas como disfunción olfatoria, trastorno conductual del sueño REM, depresión y constipación, entre otras, preceden a la aparición de los síntomas motores. Además, las neuroimágenes han permitido reconocer algunos de los sujetos en riesgo de presentar EP a partir de síntomas tempranos o en portadores de mutaciones genéticas asociadas con la EP. En este artículo revisamos la información disponible sobre el diagnóstico en la etapa temprana de la EP, antes de los síntomas motores y cómo esta estrategia puede ser de utilidad en el mejor tratamiento de esta población de pacientes.

Palabras clave
enfermedad de Parkinson, diagnóstico precoz, disfunción olfatoria, trastorno conductual del REM, neuroimágenes funcionales


Artículo completo
(castellano)
Extensión:  +/-8.48 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Early Diagnosis in Parkinson's Disease

Abstract
Parkinson's disease (PD) is a neurodegenerative disorder clinically characterised by motor symptoms, those manifestations arise after an extensive loss of dopaminergic neurons in the substantia nigra. In the last decade evidence had arrived showing us that the onset of the neurodegeneration in PD probably began many years before the onset of the motor symptoms. Additionally non-motor manifestations as olfactory dysfunction, REM behavioural disorder, depression and constipation also arise earlier than the motor manifestations in the course of the disease. Neuroimages are useful for the recognition of subjects at risk to develop PD, from those with early non-motor manifestations or from genetically mutations associated with familiar PD. In this article we review the available evidence about the diagnostic of PD in the early non motor stage and how this approach could help us to improve the treatment of PD patients.

Key words
Parkinson's disease, early diagnosis, olfactory dysfunction, REM behavioural disorder, functional neuroimages

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología, Salud Mental
Relacionadas: Atención Primaria, Diagnóstico por Imágenes, Diagnóstico por Laboratorio, Educación Médica, Gastroenterología, Geriatría, Medicina Familiar, Medicina Interna, Otorrinolaringología



Comprar este artículo
Extensión: 8.48 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Carlos Andrés Juri Clavería, Pontificia Universidad Católica de Chile, Marcoleta 352. Segundo Piso, Santiago, Chile
Bibliografía del artículo
1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 5(1):75-86, 2006.
2. World Health Organization. Neurological disorders: public health challenges. Geneva: World Health Organization; 2006.
3. Wolters EC, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm Suppl 70(70):309-319, 2006.
4. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 19(10):1196-1202, 2004.
5. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24(2):197-211, 2003.
6. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 14(2):223-36; discussion 222, 2002.
7. Louis ED. The shaking palsy, the first forty-five years: a journey through the British literature. Mov Disord 12(6):1068-1072, 1997.
8. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70(70):9-15, 2006.
9. Juri CC, Chana CP. Levodopa for Parkinson's disease: What have we learned? Rev Med Chil 134(7):893-901, 2006.
10. Shults CW. Lewy bodies. Proc Natl Acad Sci USA 103(6):1661-1668, 2006.
11. Ross CA, Poirier MA. Opinion: What is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 6(11):891-898, 2005.
12. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 59(4):591-596, 2006.
13. Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5(5):424-432, 2006.
14. Eisensehr I, v Lindeiner H, Jager M, Noachtar S. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography? J Neurol Sci 186(1-2):7-11, 2001.
15. Iranzo A, Santamaria J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep 28(2):203-206, 2005.
16. De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, et al. Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 130(Pt 2):450-456, 2007.
17. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17(3):146-157, 2004.
18. Iranzo A, Molinuevo JL, Santamaria J, Serradell M, Marti MJ, Valldeoriola F, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5(7):572-577, 2006.
19. Mazza S, Soucy JP, Gravel P, Michaud M, Postuma R, Massicotte-Marquez J, et al. Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 67(9):1618-1622, 2006.
20. Fantini ML, Postuma RB, Montplaisir J, Ferini-Strambi L. Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder. Brain Res Bull 70(4-6):386-390, 2006.
21. Stiasny-Kolster K, Clever SC, Moller JC, Oertel WH, Mayer G. Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. Brain 130(Pt 2):442-449, 2007.
22. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 123(Pt 6):1155-1160, 2000.
23. Eisensehr I, Linke R, Tatsch K, Kharraz B, Gildehaus JF, Wetter CT, et al. Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 26(5):507-512, 2003.
24. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 16(4):622-630, 2001.
25. Boeve BF, Lin SC, Strongosky A, Dickson DW, Wszolek ZK. Absence of rapid eye movement sleep behavior disorder in 11 members of the pallidopontonigral degeneration kindred. Arch Neurol 63(2):268-272, 2006.
26. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66(6):845-851, 2006.
27. Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 20(11):1439-1448, 2005.
28. Ozekmekci S, Apaydin H, Kilic E. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clin Neurol Neurosurg 107(4):306-309, 2005.
29. Henderson JM, Lu Y, Wang S, Cartwright H, Halliday GM. Olfactory deficits and sleep disturbances in Parkinson's disease: a case-control survey. J Neurol Neurosurg Psychiatry 74(7):956-958, 2003.
30. Quinn NP, Rossor MN, Marsden CD. Olfactory threshold in Parkinson's disease. J Neurol Neurosurg Psychiatry 50(1):88-89, 1987.
31. Ward CD, Hess WA, Calne DB. Olfactory impairment in Parkinson's disease. Neurology 33(7):943-946, 1983.
32. Scherfler C, Schocke MF, Seppi K, Esterhammer R, Brenneis C, Jaschke W, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 129(Pt 2):538-542, 2006.
33. Mueller A, Abolmaali ND, Hakimi AR, Gloeckler T, Herting B, Reichmann H, et al. Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm 112(10):1363-1370, 2005.
34. Huisman E, Uylings HB, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 19(6):687-692, 2004.
35. Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 254(1):84-90, 2007.
36. Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. 99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64(10):1716-1720, 2005.
37. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 22(6):839-842, 2007.
38. Ross GW, Abbott RD, Petrovitch H, Tanner CM, Davis DG, Nelson J, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21(12):2062-2067, 2006.
39. Markopoulou K, Larsen KW, Wszolek EK, Denson MA, Lang AE, Pfeiffer RF, et al. Olfactory dysfunction in familial parkinsonism. Neurology 49(5):1262-1267, 1997.
40. Ponsen MM, Stoffers D, Booij J, Van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56(2):173-181, 2004.
41. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 50(1):34-41, 2001.
42. Marras C, Goldman S, Smith A, Barney P, Aston D, Comyns K, et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord 20(6):687-693, 2005.
43. Montgomery EB,Jr, Lyons K, Koller WC. Early detection of probable idiopathic Parkinson's disease: II. A prospective application of a diagnostic test battery. Mov Disord 15(3):474-478, 2000.
44. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113(4):211-220, 2006.
45. Krogh K, Ostergaard K, Sabroe S, Laurberg S. Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand 117(1):60-64, 2008.
46. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57(3):456-462, 2001.
47. Ueki A, Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 251(Suppl.7):vII18-23, 2004.
48. Au WL, Adams JR, Troiano A, Stoessl AJ. Neuroimaging in Parkinson's disease. J Neural Transm Suppl 70(70):241-248, 2006.
49. Raff U, Hutchinson M, Rojas GM, Huete I. Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation. Acad Radiol 13(6):721-727, 2006.
50. Dagher A, Nagano-Saito A. Functional and anatomical magnetic resonance imaging in Parkinson's disease. Mol Imaging Biol 9(4):234-242, 2007.
51. Tinaz S, Schendan HE, Stern CE. Fronto-striatal deficit in Parkinson's disease during semantic event sequencing. Neurobiol Aging, 2006.
52. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 78(3):254-259, 2007.
53. Berg D. Transcranial sonography in the early and differential diagnosis of Parkinson's disease. J Neural Transm Suppl 70(70):249-254, 2006.
54. Berg D, Siefker C, Ruprecht-Dorfler P, Becker G. Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56(1):13-17, 2001.
55. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 9(1):1-13, 2006.
56. Berg D. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. J Neural Transm Suppl 71(71):123-132, 2006.
57. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord 21(1):94-98, 2006.
58. Phelps M. PET: molecular imaging and its biological applications. 1st ed.: Springer; 2004.
59. Adams JR, Van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128(Pt 12):2777-2785, 2005.
60. Khan NL, Scherfler C, Graham E, Bhatia KP, Quinn N, Lees AJ, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology 64(1):134-136, 2005.
61. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 127(Pt 6):1332-1342, 2004.
62. Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 52(6):849-853, 2002.
63. Linazasoro G. Classical Parkinson disease versus Parkinson complex--reflections against staging and in favour of heterogeneity. Eur J Neurol 14(7):721-728, 2007.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517